Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters

Alzheimer Disease Clinical Trial

Official title:

Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03408041
• Other study ID #: CHUB-parameters Alzheimer
• Status: Completed
• Phase: N/A
• First received: January 17, 2018
• Last updated: January 17, 2018
• Start date: May 1, 2016
• Est. completion date: October 1, 2017

Study information

• Verified date: January 2018
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more than 5 years. In clinical practice, the hippocampal volume, measured by the Scheltens index, is currently used as a marker of the progression of the disease.

The purpose of this study is to determine whether the patient's sex, age and ethnicity can influence the delay in the expression of cognitive troubles reported by the family at the first medical consultation, as well as to determine if there is a correlation between the delay reported by the family and the Scheltens index.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 129
• Est. completion date: October 1, 2017
• Est. primary completion date: October 1, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Alzheimer Disease patients admitted in the 'Memory Clinic' of the CHU Brugmann Hospital between 01-01-2010 and 31-01-2013. Diagnose according to the Dubois criteria

Exclusion Criteria:

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Other:
• Medical file data extraction
Medical file data extraction

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Murielle Surquin

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Age	Age	Between 01-01-2010 and 31-01-2013
Primary	Sex	Sex	Between 01-01-2010 and 31-01-2013
Primary	Ethnic origin	Ethnic origin	Between 01-01-2010 and 31-01-2013
Primary	Symptoms-diagnose time interval	Interval of time between the apparition of the first symptoms, as reported by the family, and the diagnose.	Between 01-01-2010 and 31-01-2013
Primary	Scheltens scale	Evaluation of the hippocampal atrophy by means of magnetic resonance imaging. Scale from 0 (normal) to 4.	Between 01-01-2010 and 31-01-2013